tbuckley/cabot-search huggingface dataset:
Stem Cell Therapy for Hypoplastic Left Heart Syndrome
Authors: Gregory J. Bittle, David Morales, Kristopher B. Deatrick, Nathaniel Parchment, Progyaparamita Saha, Rachana Mishra, Sudhish Sharma, Nicholas Pietris, Alexander Vasilenko, Casey Bor, Chetan Ambastha, Muthukumar Gunasekaran, Deqiang Li, Sunjay Kaushal
Journal: Circulation Research (2018)

Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete 3-staged surgical palliation, there is significant morbidity because of progressive and ultimately intractable right ventricular failure. For this reason, there is interest in developing novel therapies for the management of right ventricular dysfunction in patients with hypoplastic left heart syndrome. Stem cell therapy may represent one such innovative approach. The field has identified numerous stem cell populations from different tissues (cardiac or bone marrow or umbilical cord blood), different age groups (adult versus neonate-derived), and different donors (autologous versus allogeneic), with preclinical and clinical experience demonstrating the potential utility of each cell type. Preclinical trials in small and large animal models have elucidated several mechanisms by which stem cells affect the injured myocardium. Our current understanding of stem cell activity is undergoing a shift from a paradigm based on cellular engraftment and differentiation to one recognizing a primarily paracrine effect. Recent studies have comprehensively evaluated the individual components of the stem cells’ secretomes, shedding new light on the intracellular and extracellular pathways at the center of their therapeutic effects. This research has laid the groundwork for clinical application, and there are now several trials of stem cell therapies in pediatric populations that will provide important insights into the value of this therapeutic strategy in the management of hypoplastic left heart syndrome and other forms of congenital heart disease. This article reviews the many stem cell types applied to congenital heart disease, their preclinical investigation and the mechanisms by which they might affect right ventricular dysfunction in patients with hypoplastic left heart syndrome, and finally, the completed and ongoing clinical trials of stem cell therapy in patients with congenital heart disease.
Abstract 19587: Clinical Predictors of Heart Failure Event or Death in Left Bundle Branch Block Patients from MADIT CRT Trial
Authors: Wojciech Zareba, Poul Eric Block Thomsen, Valentina Kutyifa, Scott McNitt, Arthur J Moss
Journal: Circulation (2012)

Background: Heart failure patients with left bundle branch block (LBBB) benefit the most from cardiac resynchronization therapy (CRT). However, cardiac events consisting of heart failure (HF) hospitalization or death continue to occur in CRT-treated LBBB patients. The aim of this study is to identify clinical variables associated with adverse outcome in CRT-treated LBBB patients. Methods: Study population consisted of 665 CRT treated LBBB patients enrolled in the MADIT-CRT. Echocardiographic data were available in 657 CRT-treated LBBB patients. HF event or death was the primary endpoint of the trial and of this analysis. Two predictive models were constructed: Model 1 without baseline echo variables and Model 2 with baseline echo variables. Patients who crossed-over at the beginning of the study from CRT-D to ICD (mostly due to inability to advance left lead) were excluded, therefore actually CRT-treated patients were only considered in the analysis. Results: Among 665 CRT-treated LBBB patients there were 101 (15.2%) with HF event or death, whichever came first. Echo-base cohort included 657 CRT-treated patients with 101 (15.4%) of them developing primary endpoints. The following clinical variables (Model 1) were predictive for HF or death in LBBB patients: male gender: HR=1.83; p=0.027, ischemic etiology: HR=1.53; p=0.049, QRS&lt;=150ms: HR=1.69; p=0.015, prior HF hospitalization: HR=1.44; p=0.076. Figure below shows the risk of primary endpoint as a function of ischemic etiology and QRS duration. Among Echo parameters (Model 2) only left atrial volume index =&gt;40 ml/m2 was predictive for endpoints: HR=2.90; p=0.002. Conclusions: LBBB patients with ischemic cardiomyopathy and QRS&lt;=150 ms derive limited benefir from CRT. Ischemic and nonischemic cardiomyopathy patients with QRS&gt;150 ms benefit the most. Increased left atrial volume indicates increased risk of cardiac events among CRT patients.
Abstract P4-04-10: Genomic profiling of multifocal breast cancer reveals inter-lesion heterogeneity
Authors: S Ahn, HJ Kim, E Kang, E-K Kim, SH Kim, JH Kim, IA Kim, SY Park
Journal: Cancer Research (2019)

Abstract Introduction: Multifocal breast cancers are common, and tend to show more aggressive clinical features than unifocal breast cancers. While each foci of multifocal breast cancers with similar histology shares the same hormone and ERBB2 receptor status in most cases, substantial genomic differences among lesions have been reported. We aimed to investigate the potential genomic differences between multifocal breast cancer lesions. Materials and methods: Twenty-one patients with multifocal breast cancer documented in the resection specimen were included. We selected two lesions with the same histology from each of these 21 patients. Capture-based targeted next generation sequencing was performed using a cancer gene panel consisting of 170 genes for single nucleotide variants (SNV) and small insertions/deletions (Indel), and copy number alterations. Results: The most frequent mutation was TP53 (38.1%), followed by PIK3CA (28.6%). Pathogenic mutations (SNV and Indel) were detected in 13 of 21 patients, of whom 11 shared oncogenic variants in the two lesions. The remaining two patients had different mutation results in TP53 and PIK3CA, respectively. Genomic heterogeneity of copy number alteration was observed in 6 (28.6%) of 21 patients, including difference of FGFR1 status in two patients and difference of FGFR2 status in one patient. Conclusion: Despite similar histologic features of multifocal tumors, genomic inter-lesion heterogeneity was identified in about one-fourth of patients. The spatial genomic heterogeneity in multifocal breast cancers needs to be considered in representative sampling and molecular tests for personalized medicine. Citation Format: Ahn S, Kim HJ, Kang E, Kim E-K, Kim SH, Kim JH, Kim IA, Park SY. Genomic profiling of multifocal breast cancer reveals inter-lesion heterogeneity [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-04-10.
羟乙基(甲基)丙烯酸酯斑贴测试
Authors: S. Rolls, M.M. Chowdhury, S. Cooper, P. Cousen, A.M. Flynn, S.A. Ghaffar, C.M. Green, A. Haworth, C. Holden, G.A. Johnston, K. Naidoo, D.I. Orton, C. Reckling, R.A. Sabroe, M. Scorer, N.M. Stone, D. Thompson, S. Wakelin, M. Wilkinson, D.A. Buckley
Journal: British Journal of Dermatology (2019)

如果皮肤接触过敏原(引起过敏的化学品),则会出现接触性过敏反应,从而敏感化。也就是说,如果皮肤再次与相同过敏原接触,则可能会发展为湿疹类反应,这种反应被称为过敏性接触性皮炎 (ACD),其影响 20% 的人口。 皮肤科医生通过斑贴测试来找出可能引起反应的物质。医生会将一系列已知过敏原涂抹于皮肤斑块上,观察哪种会引起反应。推荐所有进行斑贴测试的人都测试斑贴测试过敏原基线(标准)系列,其目的在于测试引起 ACD 的最常见过敏原。 (甲基)丙烯酸酯化学品是水晶指甲、光疗指甲和指甲油的主要成分。(甲基)丙烯酸酯有多个类型。来自英国 15 个中心的本次研究的作者决定在 2016-7 斑贴测试基线系列中在凡士林中添加 2% 的 2-羟乙基甲基丙烯酸酯 (2-HEMA),旨在检测使用水晶指甲的患者中的 ACD。然后对有(甲基)丙烯酸酯接触史的患者或 2-HEMA 测试阳性患者使用更简短系列的 8 种(甲基)丙烯酸酯过敏原进行选择性测试。 在 5,920 名患者中,1.7% (102) 对 2-HEMA 过敏,2.4% (140) 对至少一种(甲基)丙烯酸酯过敏。在未对所有患者进行 2-HEMA 测试的情况下,遗漏了 0.6% (36) 的(甲基)丙烯酸酯过敏患者。94% 的过敏患者为女性。37/140 人因在指甲行业工作而致敏,97 人因佩戴水晶指甲而致敏。仅 6 人因接触其他来源(外科用胶水、医用黏合剂、油墨)而出现过敏。 作者推荐,应向英国斑贴测试基线系列添加 2-HEMA 2% 凡士林,而且建议使用标准化简短系列的 15 种(甲基)丙烯酸酯化学品,该系列可能检测大多数的(甲基)丙烯酸酯过敏。
A multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)
Authors: J-MA Nabholtz, K.A. Alsaleh, A. Bounedjar, M. Oukkal, H.M. El-Zawahry, K. Bouzid, H Abdel Razek, H. Mahfouf, A. Bensalem, A. Saadeddin, T. Filali, B. Larbaoui, O. Abulkhair, M. Al-Foheidi, H. Boussen, J. ayari, M. Ghosn, N. Abdel-Aziz, F. Dabouz, S. Kullab
Journal: Annals of Oncology (2019)
Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion
Authors: Ross A. Rowsey, Stephanie A. Smoley, Cynthia M. Williamson, George Vasmatzis, James B. Smadbeck, Yi Ning, Patricia T. Greipp, Nicole L. Hoppman, Linda B. Baughn, Rhett P. Ketterling, Jess F. Peterson
Journal: Blood Cancer Journal (2019)

Abstract The TCF3/PBX1 gene fusion is a recurrent genetic abnormality in pediatric B-lymphoblastic leukemia/lymphoma (B-ALL/LBL). While dual-color, dual-fusion fluorescence in situ hybridization (D-FISH) probes can detect TCF3/PBX1 fusions, further characterization of atypical TCF3 FISH patterns as indicated by additional or diminished TCF3 signals is currently limited. Herein we describe the use of a next-generation sequencing assay, mate-pair sequencing (MPseq), to characterize typical and cryptic TCF3/PBX1 fusions and to identify TCF3 translocation partners based on results obtained from our laboratory-developed TCF3/PBX1 D-FISH probe set. MPseq was performed on 21 cases of pediatric B-ALL/LBL with either TCF3/PBX1 fusion, or no TCF3/PBX1 fusion but with additional or diminished TCF3 signals obtained by our PBX1/TCF3 D-FISH probe set. In addition, MPseq was performed on one pediatric B-ALL/LBL case with an apparently normal karyotype and abnormal TCF3 break-apart probe results. Of 22 specimens successfully evaluated by MPseq, 13 cases (59%) demonstrated TCF3/PBX1 fusion, including three cases with previously undescribed insertional rearrangements. The remaining nine cases (41%) harbored various TCF3 partners, including six cases with TCF3/ZNF384 , and one case each with TCF3/HLF , TCF3/FLI1 and TCF3/TEF . Our results illustrate the power of MPseq to characterize TCF3 rearrangements with increased precision and accuracy over traditional cytogenetic methodologies.
A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
Authors: W. Harb, A. Patnaik, D. Mahalingam, J. Liu, P.Y. Wen, G.I. Shapiro, A.J. Bullock, D. Juric, L. Zheng, K. Moore, M. Patel, R. Guttendorf, S. Wang, K. Kerstein, G. Berk, M.J. Cieslewicz, J. Watnick
Journal: Annals of Oncology (2019)
Interim analysis of a single arm phase II study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy
Authors: T. Wise-Draper, S. Haque, A. Steele, S. Desai, T. Harris, M.K. Riaz, J.C. Morris, V. Takiar, M. Nagasaka, R. Jandarov, A. Sukari
Journal: Annals of Oncology (2019)
Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus
Authors: KatherineEsposito, DarioGiugliano, FrancescoNappo, RaffaeleMarfella
Journal: Circulation (2004)

Background— Postprandial hyperglycemia may be a risk factor for cardiovascular disease. We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients. Methods and Results— We performed a randomized, single-blind trial on 175 drug-naive patients with type 2 diabetes mellitus (93 men and 82 women), 35 to 70 years of age, selected from a population of 401 patients who participated in an epidemiological analysis assessing the relation of postprandial hyperglycemia to surrogate measures of atherosclerosis. Eighty-eight patients were randomly assigned to receive repaglinide and 87 patients to glyburide, with a titration period of 6 to 8 weeks for optimization of drug dosage and a subsequent 12-month treatment period. The effects of repaglinide (1.5 to 12 mg/d) and glyburide (5 to 20 mg/d) on CIMT were compared by usi...
A phase II trial of induction epirubicin, oxaliplatin, and flourouracil, surgery and post-operative concurrent cisplatin and fluorouracil chemoradiotherapy (CRT) in patients (pts) with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
Authors: Michael J. McNamara, Thomas W. Rice, Lisa A. Rybicki, Cristina P. Rodriguez, Gregory M. M. Videtic, Jerrold P. Saxton, Kevin L. Stephans, John Greskovich, Davendra Sohal, David P. Mason, Sudish C. Murthy, Denise I. Ives, Joanna Bodmann, David J. Adelstein
Journal: Journal of Clinical Oncology (2013)

4087 Background: In pts with LRA ACA of the E/GEJ, CRT and surgery results in excellent locoregional control. Distant failure remains common, however, suggesting potential benefit from additional chemotherapy. This single arm phase II study investigated the addition of induction chemotherapy to surgery and post-operative CRT. Methods: Pts with an ultrasound-based clinical stage of T3, N1 or M1a (AJCC 6 th ) ACA of the E/GEJ were eligible. Induction chemotherapy with epirubicin 50mg/m2 d1, oxaliplatin 130mg/m2 d1, and flourouracil 200mg/m2/day continuous infusion for 3 weeks, was given every 21 days for 3 courses and was followed by surgical resection. Adjuvant CRT consisted of 50-55Gy at 1.8-2.0 Gy/d and 2 courses of cisplatin (20mg/m2/d) and flourouracil (1000mg/m2/d) given as 96 hour infusions during weeks 1 and 4 of radiotherapy. Results: Between 2/08 and 1/12, 60 evaluable pts enrolled; 95% male, 97% white and 78% with GEJ tumors. Resection was accomplished in 54 pts (90%) and adjuvant CRT in 48 (80%). Toxicity included 1 death during induction (2%), and 2 post-operative deaths (4%). Unplanned hospitalization was required in 18% of pts during induction and 19% during adjuvant CRT. Induction chemotherapy produced a symptomatic response in 79% of pts, a clinical (ultrasound) response in 48% and a pathologic response in 41% (5% complete). With a median follow-up of 31 months, the Kaplan-Meier 3-year projected locoregional control (LRC) is 84%, distant metastatic control (DMC) 44%, relapse-free survival (RFS) 39%, and overall survival (OS) 42%. Symptomatic response to induction and the percentage of remaining viable tumor at surgery proved the strongest predictors of DMC, RFS, and OS. Conclusions: Induction chemotherapy, surgery and adjuvant CRT is feasible and produces outcomes similar to other multimodality treatment schedules in LRA E/GEJ ACA. Despite excellent LRC, projected DMC and OS remain poor. A symptomatic response to induction and less residual viable tumor at surgery are associated with improved outcomes. Clinical trial information: NCT00601705.
Determinants of inequalities in life expectancy: an international comparative study of eight risk factors
Authors: Johan P Mackenbach, José Rubio Valverde, Matthias Bopp, Henrik Brønnum-Hansen, Patrick Deboosere, Ramune Kalediene, Katalin Kovács, Mall Leinsalu, Pekka Martikainen, Gwenn Menvielle, Enrique Regidor, Wilma J Nusselder
Journal: The Lancet Public Health (2019)

BackgroundSocioeconomic inequalities in longevity have been found in all European countries. We aimed to assess which determinants make the largest contribution to these inequalities.MethodsWe did an international comparative study of inequalities in risk factors for shorter life expectancy in Europe. We collected register-based mortality data and survey-based risk factor data from 15 European countries. We calculated partial life expectancies between the ages of 35 years and 80 years by education and gender and determined the effect on mortality of changing the prevalence of eight risk factors—father with a manual occupation, low income, few social contacts, smoking, high alcohol consumption, high bodyweight, low physical exercise, and low fruit and vegetable consumption—among people with a low level of education to that among people with a high level of education (upward levelling scenario), using population attributable fractions.FindingsIn all countries, a substantial gap existed in partial life expectancy between people with low and high levels of education, of 2·3–8·2 years among men and 0·6–4·5 years among women. The risk factors contributing most to the gap in life expectancy were smoking (19·8% among men and 18·9% among women), low income (9·7% and 13·4%), and high bodyweight (7·7% and 11·7%), but large differences existed between countries in the contribution of risk factors. Sensitivity analyses using the prevalence of risk factors in the most favourable country (best practice scenario) showed that the potential for reducing the gap might be considerably smaller. The results were also sensitive to varying assumptions about the mortality risks associated with each risk factor.InterpretationSmoking, low income, and high bodyweight are quantitatively important entry points for policies to reduce educational inequalities in life expectancy in most European countries, but priorities differ between countries. A substantial reduction of inequalities in life expectancy requires policy actions on a broad range of health determinants.FundingEuropean Commission and Network for Studies on Pensions, Aging, and Retirement.
Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Authors: A. Papakonstantinou, A. Matikas, M. Hellström, H. Johansson, G. Steger, R. Greil, S. Loibl, M. Gnant, V. Moebus, M. Untch, T. Foukakis, J. Bergh
Journal: Annals of Oncology (2019)
State-Level Approaches to Expanding Pharmacists’ Authority to Dispense Naloxone May Affect Accessibility—Reply
Authors: Rahi Abouk, Rosalie Liccardo Pacula, David Powell
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A phase I study of HMPL-523, a selective oral anti-spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma
Authors: N. Fowler, W. Jurczak, R. Cordoba Mascunano, P. Abrisqueta Costa, P. Strati, C. Yang, M. Kania, J. Kauh, A.J.M. Ferreri
Journal: Annals of Oncology (2019)
Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis of a multicenter ‘real-world’ patients (pts) series
Authors: A. Orlandi, E. Iattoni, L. Pizzuti, M.A. Fabbri, A. Botticelli, C. Di Dio, A. Palazzo, G. Garufi, G. Indellicati, D. Alesini, L. Carbognin, I. Paris, A. vaccaro, L. Moscetti, A. Cassano, P. Vici, D. Giannarelli, P. Marchetti, E. Bria, G. Tortora
Journal: Annals of Oncology (2019)
Assessing liver function: Diagnostic efficacy of parenchymal enhancement and liver volume ratio during hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) enhanced-magnetic resonance imaging (MRI) studies
Authors: A. Pecorelli, E.B. Orsini, S. Famularo, D. Bernasconi, L. Gianotti, S. Sironi, D. Ippolito
Journal: Journal of Hepatology (2018)
Avelumab for advanced Merkel cell carcinoma in the Netherlands: A nationwide survey
Authors: S. Levy, M.J.B. Aarts, F.A. Eskens, K. Keymeulen, L. Been, D.J. Grünhagen, A.C.J. van Akkooi, M. Jalving, M.E.T. Tesselaar
Journal: Annals of Oncology (2019)
Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)
Authors: A. Necchi, Y. Fradet, J. Bellmunt, R. de Wit, J.-L. Lee, L. Fong, N.J. Vozelgang, M.A. Climent, D.P. Petrylak, T.K. Choueiri, W.R. Gerritsen, H. Gurney, D.I. Quinn, S. Culine, C.N. Sternberg, K. Nam, T.L. Frenkl, J.L. Godwin, D.F. Bajorin, D.J. Vaughn
Journal: Annals of Oncology (2019)
Turning the Heat up a Notch in Biclonal Lymphoproliferative Disorders
Authors: Helen Fogarty, Anita Dowling, David O'Brien, Christopher Laurence Bacon, Patrick Thornton, Brian Hennessy, Hilary M O'Leary, Gerard Crotty, Robert Henderson, James Nolan, Elisabeth A. Vandenberghe, Fiona M Quinn
Journal: Blood (2016)
The expression of MMR, CD133 and the presence of p53 wt predict the response to cabazitaxel in malignant neural tumours cell lines
Authors: K. Doello, C. Mesas, G. Perazzoli, C. García-Collado, M.J. Gándara, R. García-Fumero, M. Fuel, R. Luque, R. Ortiz, C. Melguizo, J.C. Prados
Journal: Annals of Oncology (2019)
HER3 ligand heregulin expression and clinical implication in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Authors: K. Yonesaka, E. Iwama, H. Hayashi, S. Suzuki, R. Kato, S. Watanabe, T. Takahama, J. Tanizaki, K. Tanaka, M. Takeda, K. Sakai, K. Azuma, Y. Chiba, S. Atagi, K. Nishio, I. Okamoto, K. Nakagawa
Journal: Annals of Oncology (2019)
Long-Term Evolution of Premature Coronary Artery Disease
Authors: Jean-Philippe Collet, Michel Zeitouni, Niki Procopi, Jean-Sébastien Hulot, Johanne Silvain, Mathieu Kerneis, Daniel Thomas, Benoit Lattuca, Olivier Barthelemy, Yoan Lavie-Badie, Jean-Baptiste Esteve, Laurent Payot, Delphine Brugier, Izolina Lopes, Abdourahmane Diallo, Eric Vicaut, Gilles Montalescot
Journal: Journal of the American College of Cardiology (2019)
Trifluridine/tipiracil in metastatic colorectal cancer: An updated multicentre real-world analysis on efficacy, safety and predictive factors
Authors: C. Stavraka, A. Pouptsis, A. Synowiec, V. Aggelis, L. Satterthwaite, S. Khan, M. Chauhan, C.E. Holden, S. Young, C. Karampera, M. Martinou, T. Mills-Baldock, M. Baxter, B.K. Eccles, T.J. Iveson, K.-K. Shiu, M.E. Hill, S. Abdel-Raouf, A. Thomas, P.J. Ross
Journal: Annals of Oncology (2019)
In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer
Authors: C. Nieto-Jiménez, E.M. Galán-Moya, V. Corrales-Sanchez, M.D.M. Noblejas López, M. Burgos, B. Domingo, J.C. Montero, J. Perez-Peña, M. Gómez-Juárez, A. Pandiella, A. Ocaña
Journal: Annals of Oncology (2019)
A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
Authors: D. Takahari, A. Kawazoe, Y. Nakamura, H. Tamura, M. Fukutani, N. Hirano, M. Wakabayashi, S. Nomura, A. Sato, K. Shitara
Journal: Annals of Oncology (2019)